June 12, 2020 / 3:19 PM / a month ago

BRIEF-Verrica Pharmaceuticals Announces Positive Results From Two New Pooled Analyses Of Phase 3 CAMP Trials Of VP-102

June 12 (Reuters) - Verrica Pharmaceuticals Inc:

* VERRICA PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM TWO NEW POOLED ANALYSES OF THE PHASE 3 CAMP TRIALS OF VP-102 IN MOLLUSCUM CONTAGIOSUM

* VERRICA PHARMACEUTICALS- PRE-SPECIFIED EXPLORATORY ANALYSIS SHOWED ALL VP-102 QUARTILES HAD STATISTICALLY SIGNIFICANTLY HIGHER PERCENTAGE OF PATIENTS

* VERRICA PHARMACEUTICALS -POST-HOC DATA SHOWED BASELINE CHARACTERISTICS PATIENT MAYBE COMPLETE LESION CLEARANCE CANDIDATE AFTER UPTO 4 VP-102 TREATMENT

* VERRICA PHARMACEUTICALS - TWO ANALYSES OF PHASE 3 CAMP TRIALS ADD TO BODY OF EVIDENCE THAT SUPPORTS SAFETY, EFFICACY PROFILE OF VP-102 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below